<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of the <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> receptor blocker, <z:chebi fb="0" ids="3347">candesartan</z:chebi> cilexetil, on <z:hpo ids='HP_0000093'>proteinuria</z:hpo> was examined in a prospective, multicenter, randomized, double-blind study in Japanese subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>This study enrolled diabetic subjects with confirmed <z:hpo ids='HP_0000093'>proteinuria</z:hpo> into four groups for 12 weeks of treatment with placebo or <z:chebi fb="0" ids="3347">candesartan</z:chebi> cilexetil 2, 4, or 8 mg </plain></SENT>
<SENT sid="2" pm="."><plain>The contribution of the angiotensin converting enzyme (ACE) gene polymorphism to the effect of <z:chebi fb="0" ids="3347">candesartan</z:chebi> cilexetil was also examined </plain></SENT>
<SENT sid="3" pm="."><plain>In 127 subjects, <z:chebi fb="0" ids="3347">candesartan</z:chebi> cilexetil showed a dose-related reduction in <z:hpo ids='HP_0000093'>proteinuria</z:hpo> after 12 weeks of treatment (F = 9.45, P = 0.0013), with a 18.1% reduction in the 4-mg group, and a 5.8% reduction in the 8-mg group, in contrast to a 32.2% increase in the placebo group, and a 0.8% increase in the 2-mg group </plain></SENT>
<SENT sid="4" pm="."><plain>These results indicate that <z:chebi fb="0" ids="3347">candesartan</z:chebi> cilexetil is useful in reducing <z:hpo ids='HP_0000093'>proteinuria</z:hpo> in diabetic subjects when compared with placebo </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, <z:chebi fb="0" ids="3347">candesartan</z:chebi> cilexetil seems to be effective in subjects with both the II and DD genotypes of the ACE gene </plain></SENT>
</text></document>